Cointime

Auris Medical

company

About

Auris Medical develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.

  • Basel,Basel-Stadt,Switzerland
  • 11 - 50

Highlights

Stock Symbol
fra:2RA1
Total Funding Amount
$22.58M Fr47.10M
Funding Rounds
5
Investors
6
Acquisition
1
Employee Profiles
7

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$12.50M
Industries
Health Care,Pharmaceutical,Therapeutics
Founded date
Apr 1, 2003
Number Of Employee
11 - 50
Operating Status
Active
Stock Symbol
fra:2RA1
Legal Name
Auris Medical Holding AG

They at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus and restore balance.

Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo.

They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$22.58M Fr47.10M
Auris Medical has raised a total of $22.58M Fr47.10M in funding over 2 rounds. Their latest funding was raised on Jul 19, 2016 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 19, 2016 Post-IPO Debt $12.50M 1 — — Detail
Nov 7, 2014 IPO — — — — Detail
Apr 16, 2013 Series C Fr47.10M 2 Sofinnova Investments
Sofinnova Partners 		— Detail
Feb 15, 2008 Series B $10.08M 3 — — Detail
Dec 1, 2007 Series A — 1 Idinvest Partners — Detail

Investors

Number of Lead Investors
Number of Investors
3
6
Auris Medical is funded by 6 investors. Sofinnova Investments and Sofinnova Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Sofinnova Investments Yes Series C
Sofinnova Partners Yes Series C
Hercules Capital — Post-IPO Debt
ZKB Pharma Vision Fund — Series B
Idinvest Partners — Series B
Lacuna — Series B

Employee Profiles

Number of Employee Profiles
7
Auris Medical has 7 current employee profiles, including Executive James Healy
James Healy
Executive
Alain Munoz
Executive
Thomas Meyer
Executive
Marcel Gremaud
Executive
Wolfgang Arnold
Executive
Show More

Acquisition

Auris Medical has acquired 1 organizations. Their most recent acquisition was Trasir Therapeutics on Jun 3, 2021. They acquired Trasir Therapeutics for 0.

Date Company Name
Industry Acquisition Type Price
Jun 3, 2021 Trasir Therapeutics
Therapeutics acquisition — Detail
Cointime
Content
Company